SIGHT-DIAGNOSTICS
9.12.2020 13:10:07 CET | Business Wire | Press release
Sight Diagnostics , the company delivering lab-grade Complete Blood Count (CBC) results in minutes, announced a distribution partnership with Phoenix Capital to extend Sight’s footprint in the Middle East. Through the partnership, Sight will provide OLO analyzers – the company’s decentralized, lab-quality diagnostic technology – to medical centers across the Middle East to help providers make quick and informed treatment decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005496/en/
Most outpatient clinics in the United Arab Emirates are currently operating mini-labs with legacy diagnostic technologies like flow cytometry, which require large, expensive machines that aren’t suited for point-of-care (POC) settings. As such, there is an increasing demand for modern POC diagnostics in the Middle East and Africa, with the market projected to reach $2.85 billion by 2024 .
Sight OLO enables fast, accurate, convenient blood diagnostics by delivering CBC results in minutes right at the point-of-care*. About the size of a toaster oven, OLO is small, compact, and light-weight, allowing for quick, simple set-up wherever it’s needed. Unlike traditional CBC analyzers, Sight OLO does not require reagents or manual quality control checks, making it easy for smaller clinics or independent practices to access and operate.
Abdullah Saeed Al Naboodah, Chairman of Phoenix Capital remarks, “We chose Sight OLO because it simply meets the needs of the clinics we distribute to. With the influx of patients due to COVID-19, having access to fast, accurate fingerprick diagnostics is essential to quickly and correctly triage and treat our clinic’s patients.”
Phoenix Capital will first distribute Sight OLO to the nine medical centers it owns across the United Arab Emirates. Over the next year, Sight will work with Phoenix Capital to start expanding OLO’s install base in the rest of the Gulf Cooperation Council region.
“We’re determined to democratize access to rapid, accurate, and convenient diagnostics in countries around the world,” says Yossi Pollak, CEO and Cofounder of Sight Diagnostics. “We’re looking forward to expanding into this new market through our partnership with Phoenix Capital to help meet the needs of emergency rooms, clinics, hospitals, and other care facilities that have been impacted by COVID-19.”
This distribution partnership follows a recent investment partnership between Phoenix Capital and OurCrowd, one of Sight’s longtime investors that recently participated in the diagnostic company’s $71 million Series D funding round. Notably, the news also follows a historic normalization agreement between Israel and the United Arab Emirates, signaling the countries’ progress in sharing resources and technology to improve healthcare together.
*Sight OLO received regulatory approval for use in the UAE and is CE Marked according to the IVD European directive at point of care settings. In the United States, Sight OLO is 510(k) cleared for use in moderate complexity laboratories; it has not yet been cleared for point-of-care use.
About Sight Diagnostics
Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing. Sight’s technology, developed over almost a decade of research, represents breakthrough innovations in diagnostic methodology. Sight’s latest blood analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes. It’s compact: designed to be used in a variety of settings. Sight OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, ParasightTM
, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the UK, the US and Israel. Learn more at www.SightDX.com
.
About Phoenix Capital
Phoenix Capital was established by Mr Abdullah Al Naboodah to help catalyze the growth of expansion-seeking entrepreneurs and businesses from around the globe and to help create a more developed and connected world. By leveraging experiences in a diverse array of industries, Phoenix Capital’s portfolio of sophisticated and wide-ranging clients and partners serve as a springboard for entities with ambition to penetrate the GCC (Gulf Cooperation Council).
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005496/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 10:00:00 CEST | Press release
Partnership to support Nethive’s next phase of growth as a leading cybersecurity services and software platform Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 09:00:00 CEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 09:00:00 CEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 08:00:00 CEST | Press release
As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Ga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
